Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02785393 · ClinicalTrials.gov registry record · Phase 1

DOX as a Potential Treatment for Methamphetamine Dependence

A Phase 1 study, sponsored by Baylor College of Medicine.

Completed
Registry status
Phase 1
Development phase
11
Enrollment target

NCT02785393: Completed Phase 1 study, sponsored by Baylor College of Medicine.

NCT02785393 is a Phase 1 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 11 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02785393, a Phase 1 study, has completed, sponsored by Baylor College of Medicine.

COMPLETED
Registry status
Phase 1
Development phase
11 participants
Enrollment target

Study Summary

The purpose of the study is to asses the potential interactions between methamphetamine and doxazosin in methamphetamine-dependent volunteers who are not seeking treatment. The study will evaluate the effects of doxazosin on the cardiovascular and subjective effects of methamphetamine in a human laboratory study. The primary objective is to determine the safety of treatment with doxazosin in methamphetamine-dependent volunteers by examining hemodynamic and subjective effects of administration of ascending doses of methamphetamine and a placebo dose during treatment with doxazosin. The secondary objective is to determine effects of treatment with doxazosin, as compared to placebo, on subjective effects produced by administration of methamphetamine or placebo

Interventions

  • DRUG Doxazosin
  • DRUG Sugar Pill

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2011-03
Est. Completion 2016-03
Phase Phase 1
Baylor College of Medicine

616 total trials

What the finished NCT02785393 record still lists

NCT02785393 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower).

The record links to 0 conditions, and to 2 interventions - of which Doxazosin is the first listed.

NCT02785393 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02785393 about?

NCT02785393 is a clinical study titled "DOX as a Potential Treatment for Methamphetamine Dependence". The purpose of the study is to asses the potential interactions between methamphetamine and doxazosin in methamphetamine-dependent volunteers who are not seeking treatment. The study will evaluate the effects of doxazosin on the cardiovascular and subjective effects of methamphetamine in a human lab...

What is the current status of trial NCT02785393?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2011-03. Estimated completion is 2016-03.

What interventions are being tested in trial NCT02785393?

The interventions under investigation include: Doxazosin (DRUG), Sugar Pill (DRUG).

Who is sponsoring clinical trial NCT02785393?

This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02785393's enrollment target sits among peer trials

11 1911th of 2000 higher than 88 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03114462 · 11 participants · Phase 1

    Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

  • NCT06039709 · 11 participants · Phase 1

    Sonodynamic Therapy in Patients With Recurrent GBM

  • NCT06425380 · 11 participants · NA

    Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

  • NCT06472661 · 11 participants · Early Phase 1

    FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02785393, the US trial registry maintained by the National Library of Medicine. NCT02785393 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.